Critical limb ischem ia (CLI) affect s up to 2% of t he patient s diagnosed wit h p eripheral arter y disea se (PAD), wit h some 1,0 0 0 new ca ses of CLI diagnosed p er 1 m illion Europ eans or Nort h A mericans ever y year [1]. Unfort unately, many patient s are ineligible for t reatment, which consist s of reva scularization eit her p ercutaneously or surgically, wit h t he latter resulting in a 25% amputation rate.
SHORT HAIRPIN RNA GENE SILENCING OF PROLYL HYDROXYLASE-2 WITH A MINICIRCLE VECTOR IMPROVES NEOVASCULARIZATION OF HINDLIMB ISCHEMIA

INTRODUCTION
Critical limb ischem ia (CLI) affect s up to 2% of t he patient s diagnosed wit h p eripheral arter y disea se (PAD), wit h some 1,0 0 0 new ca ses of CLI diagnosed p er 1 m illion Europ eans or Nort h A mericans ever y year [1] . Unfort unately, many patient s are ineligible for t reatment, which consist s of reva scularization eit her p ercutaneously or surgically, wit h t he latter resulting in a 25% amputation rate.
Therap eutic angiogenesis represent s an alter native t reatment modality for t hese patient s. However, despite t he numerous p ositive result s in animal st udies, clinical t rials using a single angiogenic factor by eit her recombinant protein or gene-ba sed for mulations have resulted in eit her negative or conflicting outcomes [2] [3] [4] [5] . To increa se t he success of gene-ba sed t herap eutic angiogenesis in t he clinical sit uation, various gene t ransfer techniques have undergone intense investigation in recent years. Nonviral pla sm id DNA is com monly used in clinical t rials due to safety concer ns wit h viral vectors, but t hese conventional pla sm ids also may provoke negative side effect s t hat affect t he gene expression. For instance, t he bacterial backb one may lead to unwanted heteroch romatin for mation t hat changes eukar yotic gene expression or induces im mune resp onses to CpG sequences [6] [7] [8] . To resolve t hese issues, an att ractive gene t ransfer tool (nonviral m inicircle (MC) pla sm id) wa s designed.
MCs are sup ercoiled DNA molecules t hat are smaller compared to conventional pla sm ids and lack a bacterial origin of replication or an antibiotic resistance gene, feat ures t hat greatly improve t he t ransgene expression b ot h in ter ms of expressed levels of gene expression a s well a s in t he p ersistence of t he gene expression [9, 10] .
As indicated ab ove, t he result s of clinical t rials using a single angiogenic (grow t h) factor were disapp ointing [11, 12] . This suggest s t hat t he expression of a single angiogenic factor such a s va scular endot helial grow t h factor (VEGF) alone may not b e suff icient to improve neova scularization [13] .
Newer t herap eutic approaches designed to circumvent t his problem utilize t he upst ream t ranscriptional factor, hyp ox ia inducible factor-1 alpha (HIF-1-alpha).
Factors expressed by t he HIF pat hway include va scular endot helial grow t h factor, f ibrobla st grow t h factor, insulin-like grow t h factor, er yt h rop oietin, and nit ric ox ide sy nt ha se, among ot hers [14, 15] . However, t he HIF-1-alpha protein ha s a lim ited biological half-life a s HIF-1-alpha is degraded in nor mox ic conditions by oxygen-dep endent prolyl hydroxyla se-2 (PHD2) [16] .
PHD2 mediates t he interaction of HIF-1-alpha wit h von Hipp el-Lindau protein ABSTRACT Aim: In t his st udy, we target t he hyp ox ia inducible factor-1 alpha (HIF-1-alpha) pat hway by short hair pin R NA (shR NA) inter ference t herapy targeting prolyl hydroxyla se-2 (shPHD2). We use t he m inicircle (MC) vector technology a s an alter native for conventional nonviral pla sm id (PL) vectors in order to improve neova scularization after unilateral hindlimb ischem ia in a murine model.
Methods and Results:
Gene expression and t ransfection eff iciency of MC and PL, b ot h in vit ro and in vivo, were a ssessed using biolum inescence imaging (BLI) and f irefly Lucifera se (Luc) rep orter gene. C57Bl6 m ice under went unilateral elect ro-coagulation of t he femoral arter y and ga st rocnem ic muscle injection wit h MC-shPHD2, PL-shPHD2, or PBS a s cont rol. Blood flow recover y (BFR) wa s monitored using La ser Doppler Per fusion Imaging (LDPI), and collaterals were visualized by im munohistochem ist r y and angiography. MC-Luc showed a 4.6-fold higher in vit ro BLI signal compared to PL-Luc. BLI signals in vivo were 4.3x10 5 ±3.3x10 5 (MC-Luc) versus 0. 4x10 5 ±0.3x10 5 (PL-Luc) at day 28 (p=0.016). Compared to PL-shPHD2 or PBS, MC-shPHD2 signif icantly improved BFR, up to 50% from day 3 until day 14 after ischem ia-induction. MC-shPHD2 signif icantly increa sed collateral density and capillar y density, a s monitored by alpha-smoot h muscle actin (α-SMA) expression and CD31 + expression, resp ectively. A ngiography data conf ir med t he histological f indings. Signif icant downregulation of PHD2 mR NA levels by MC-shPHD2 wa s conf ir med by quantitative PCR (qPCR). Finally, Wester n blot analysis conf ir med signif icant higher levels of HIF-1-alpha protein by MC-shPHD2, compared to PL-shPHD2 and PBS.
Conclusions:
This st udy provides initial evidence of a new p otential t herap eutic approach for p eripheral arter y disea se (PAD). The combination of HIF-1-alpha pat hway targeting by shPHD2 wit h t he robust nonviral MC pla sm id improved p ost-ischem ic neova scularization, ma king t his approach a prom ising p otential t reatment option for critical limb ischem ia.
gene (MC-Luc), using Lip ofectam ine 20 0 0 (Invit rogen, Carlsbad, CA, USA) according to t he manufact urer's protocol. C2C12 cells show rapid proliferation wit h a doubling time of approx imately 19 h r in vit ro [21] . In order to more closely resemble t he in vivo conditions of slower proliferating cells, C2C12 cells were exp osed to 9 0 0 0 Rad 3 h r b efore t ransfection, resulting in an optimal proliferation patter n (Supplemental Figure 1) . Proliferation of cells wa s quantif ied by using a 3-(4,5-dimet hylt hiazolyl-2)-2,5-diphenyltet razolium brom ide (MTT) proliferation a ssay according to t he manufact urer's protocol. As a cont rol, non-irradiated mouse C2C12 myobla st cells were used. Vivo Imaging System (Alameda, Califor nia) on days 1, 3, 5, and 7, and weekly t hereafter until t he endp oint on day 28, by an investigator blinded to st udy conditions (E.J.B.), a s previously describ ed [23, 24] . BLI signals were quantif ied in ma x imum photons p er second p er centimeter squared p er steradian (p/s/cm 2 / sr). To compare t he duration of gene expression in vit ro, irradiated C2C12 cells were imaged using BLI at 3, 24, and 48 h r after t ransfection.
Experimental animals
Ten-week old C57Bl6 m ice (Jack son lab orator y) were used (10 m ice p er group). All animal exp eriment s were p er for med after approval of t he relevant 
Surgical procedure to induce hindlimb ischemia
C57Bl6 m ice p ossess a well-k nown fa st recover y after hindlimb ischem ia induction [25] . Mice injected wit h MC-shPHD2 were exp ected to have enhanced blood flow recover y a s compared to cont rols. Double elect ro-coagulation of In t he present st udy, we combine t he advantages of MC wit h t he angiogenic effect s of t he HIF-1-alpha pat hway, t h rough shR NA k nockdown of PHD2 in a murine hindlimb ischem ia model. We demonst rate t hat t he combination of t hese t wo st rong concept s offers a prom ising new avenue for improving p ost-ischem ic neova scularization in t he fut ure.
METHODS
Construction of MC plasmids and MC DNA
The MC pla sm ids are const r ucted and produced a s describ ed earlier [6, 18] .
Briefly, for t he production of MC, ubiquitin promoter-driving f irefly lucifera se (Luc) is amplif ied wit h Luc for ward and Luc reverse primers using pUbiquitinLuc a s a template. The mouse PHD2 gene is cloned, a s describ ed earlier, wit h TGTGAGGAACTTGAGATCT a s t he short hair pin scramble (shScramble) antisense sequence, and wit h t he fragment No 2 k nockdown site inserted after H1 promoter in t he vector pSup er [18] . The m inicircle DNA pla sm id used here (a gift from Dr. Mark Kay, Stanford University) wa s produced a s describ ed previously [6, 20] .
Cell culture and transfection
Mouse C2C12 cells were cult ured in DMEM containing 10% fetal b ovine ser um 
Protein extraction and Western blot analysis
Protein from ga st rocnem ius muscle (n=14) wa s ex t racted and analyzed a s previously describ ed [18, 29] . Cellular lysed homogenates in radioim munoprecipitation a ssay buffer were isolated for protein concent ration deter m ination wit h a bicinchoninic acid a ssay (Ther mo Scientif ic, Rockford, IL, USA). Equal amount s of protein were loaded p er well (20μg of protein p er well). Samples were ex t racted wit h a sample buffer (Biorad, Hercules, CA, USA) containing 50 mM dit hiot h reitol a s a reducing agent for 5 m inutes at 95°C, resolved by p olyacr ylam ide gel elect rophoresis, and t ransferred to p oly vinylidene fluoride membranes. The membranes were t hen blocked wit h 5% m ilk/ Tris-buffered saline-Tween (TBST) for 1 h r at room temp erat ure, incubated wit h t he appropriate primar y antib ody at 4°C over night, and wa shed wit h TBST. Before surger y, m ice were anest hetized wit h an int rap eritoneal injection of a combination of m idazolam (5 mg/ kg, Roche), medetom idine (0.5 mg/ kg, Orion), and fentanyl (0.05 mg/ kg, Janssen). A skin incision wa s made unilaterally from t he left inguinal region to t he k nee. For a double coagulation model such a s t hat used in t his st udy, b ot h t he com mon femoral arter y and t he p opliteal arter y were dissected from t he nerve and vein a s describ ed b efore [25] . A n elect rocoagulation of t he com mon femoral arter y wa s p er for med and followed by an elect ro-coagulation of t he p opliteal arter y. After surger y, t he skin wa s closed wit h 6-0 Et hilon sut ures.
Laser Doppler perfusion imaging
To compare t he neova scularization effect s wit h equimolar concent rations, 25 μg of PL-shPHD2 and 12.5 μg of MC-shPHD2 were injected into t he left ga st rocnem ius muscles of C57Bl6 m ice (n=10/group) 24 h r after t he induction of hindlimb ischem ia. Additional m ice (n=10) were injected wit h PBS (50 μl) a s a cont rol. Mea surement s of paw p er fusion were p er for med of t he mouse hindlimbs b efore, directly after, biweekly until day 14, and weekly until 4 week s after t he surgical procedure wit h La ser Doppler Per fusion Imaging (LDPI) (Moor Inst r ument s). Per fusion wa s expressed a s a ratio of t he left (ischem ic) to right (non-ischem ic) paw, a s previously describ ed [26] .
Histological analysis
Additional animals were sacrif iced 10 days after ischem ia induction followed by injection of MC-shPHD2, PL-shPHD2, or PBS, wit h t heir calf and adductor muscles removed and f ixed wit h 4% for maldehyde and paraff in-emb edded.
Serial 5 μm cross-sections were generated. Sections were re-hydrated and endogenous p erox ida se activity wa s blocked for 20 m inutes in met hanol containing 0.3% hydrogen p erox ide. Capillaries and collaterals were visualized using antib odies recognizing CD31 on endot helial cells or α-smoot h muscle actin (SMA) in smoot h muscle cells, a s previously describ ed [26, 27] . Quantif ication of lab eled tissue sections wa s p er for med using ImageJ (9 sections p er mouse were analyzed to obtain t he mean p er animal, and 5 animals p er group were less t han 5% in all m ice. Mice injected wit h MC-shPHD2 showed signif icantly improved blood flow recover y, up to 50% from day 3 until day 14 after ischem ia induction a s compared to m ice injected wit h PL-shPHD2 or PBS (Figure 3 ).
Injection of PL-shPHD2 did not improve blood flow recover y signif icantly a s compared to PBS injection.
Increase in collateral and capillary density in post-ischemic skeletal muscle after MC-shPHD2 injections. To st udy collateral arter y for mation at t he tissue level, ischem ic skeletal muscles were harvested 10 days after hindlimb ischem ia induction, and im munohistochem ical staining wa s p er for med.
Mice injected wit h MC-shPHD2 showed a signif icant increa se in collateral density, a s mea sured by SMA expression, in t he p ost-ischem ic adductor muscle a s compared to m ice injected wit h PL-shPHD2 or PBS (3.5±0.5 vs. Quantitative PCR analysis of PHD2 mRNA expression. Additional C57BL6 m ice were subjected to hindlimb ischem ia followed by injection of MC-shPHD2, PL-shPHD2, or PBS, to a ssess PHD2 mR NA and HIF-1-alpha protein expression at 7 days after surger y. MC-shPHD2 injection signif icantly decrea sed t he mean PHD2 mR NA expression in ga st rocnem ius muscles, wit h delta Ct levels of 0.28±0.022, compared to PL-shPHD2 and PBS (0.35±0.016 and 0.36±0.026, resp ectively; p<0.05) (Figure 6 ).
Western blot analysis of HIF-1-alpha protein expression. Wester n blot
Statistical analysis
Result s are expressed a s mean ± sem. Comparisons b et ween means were p er for med using an indep endent T-test. For rep eated mea sures, 1-way rep eated mea sures ANOVA wit h p ost-hoc Bonferroni-Holm's correction wa s used.
P-values <0.05 were considered statistically signif icant. All calculations were p er for med in SPSS 19.0.
RESULTS
Evaluation of minicircle vectors versus regular plasmid vectors in vitro.
To a ssess t he t ransfection eff iciency, MC-Luc and PL-Luc were used in equimolar amount s to t ransfect mouse C2C12 cells. Luc wa s evaluated by BLI.
MC-Luc showed a higher Luc expression compared to PL-Luc, wit h a 4.6-fold higher BLI signal at 24 h r and a 4. 4-fold higher BLI signal at 48 h r in irradiated C2C12 cells (Figure 1) . As a cont rol, in non-irradiated cells MC-Luc showed 2.5-fold higher Luc expression compared to PL-Luc at 24 h r after t ransfection (Supplemental Figure 2) .
Comparison of MC versus regular plasmids in vivo. Equimolar amount s
of MC-Luc and PL-Luc were injected into t he left or right mouse ga st rocnem ius muscles, resp ectively, to deter m ine expression levels in C57Bl6 m ice in vivo. Gene expression wa s followed by BLI from day 0 until day 28. MC-Luc injection showed a signif icantly higher Luc activity compared to PL-Luc from day 3 until t he end p oint at day 28, wit h BLI of 6.9 x10 3 ±1. 7x10 3 versus 3.6x10 3 ±0. 
Injection of MC encoding shPHD2 improves post-ischemic blood flow recovery.
To exam ine whet her MC-shPHD2 could improve p ost-ischem ic neova scularization in vivo a s compared to PL-shPHD2 or PBS, hindlimb ischem ia wa s p er for med in C57BL6 m ice followed by injection of MC-shPHD2, PL-shPHD2, or PBS, resp ectively. After double elect ro-coagulation of b ot h t he com mon femoral arter y and t he p opliteal arter y, blood flow decrea sed to t ransfection eff iciencies. To a ssess t ransfection eff iciency in vit ro, MC-Luc and PL-Luc were used in equimolar amount s to t ransfect irradiated mouse C2C12 [37]. The mechanism of enhanced t ransgene expression of MCs is unclear, but may result from t he elim ination of t he unnecessar y pla sm id sequences, in particular CPG islands, which can lead to t ranscriptional gene silencing in vivo. In addition, t he smaller size of MCs may confer b etter ex t racellular and int racellular bioavailability and t herefore improve gene deliver y prop erties [8] .
Previous st udies on t herap eutic angiogenesis have demonst rated regression of neovessels a s time progressed due to a drop in expression after gene t ransfer [38] [39] [40] [41] . By using m inicircle a s a vector, we and ot hers have shown t hat gene expression levels are high up to 4 week s after t ransfection [6] .
Additionally, previous st udies have shown t hat t he t herap eutic window ranges from 1 to 3 week s, wit h complete blood flow recover y in unt reated cont rol animals after t hese time p oint s [25] . Therefore, we used a single adm inist ration to analyze t he effect on neova scularization. No signif icant neovessel regression wa s seen in our st udy. MC-shPHD2 t reatment resulted in 10 0% blood flow recover y 3 week s after ischem ia induction. A non-signif icant decrea se in blood flow wa s seen at 28 days in t his group. This m ight b e explained by t he relative decrea se in HIF-1-alpha levels in t he nor mox ic paws. This is in concordance wit h t he previously mentioned st udies in which gene expression tends to vanish in t he absence of an angiogenic stimulus. However, we b elieve t hat restoring t he blood flow to t he downst ream tissue, and t hus resolving t he ischem ia in t he affected area s, is also an imp ortant factor t hat may explain t he small decline in p er fusion. After for mation of suff icient new collaterals and consequently repair of t he blood flow to t he ischem ic tissue, part of t he newly for med collaterals analysis of HIF-1-alpha protein expression in t he ga st rocnem ius muscles at day 7 after surger y showed a signif icantly increa sed mean relative HIF-1-alpha protein level in t he MC-shPHD2-t reated group of 1.0±0.058, compared to PL-shPHD2 t reatment (0.80±0.058) and PBS t reatment (0.67±0.12) (p<0.05 for b ot h) ( Figure   7 ).
DISCUSSION
To our k nowledge, t his is t he f irst st udy t hat combines t he advantages of stimulating t he angiogenic p otential of t he HIF-1-alpha pat hway by shR NA inter ference of PHD2 wit h t he nonviral m inicircle vector technology. Our result s indicate t hat MC-shPHD2 improves p ost-ischem ic neova scularization in a hindlimb ischem ia mouse model, ma king t his approach an att ractive p otential t reatment option for critical limb ischem ia. Additionally, t he inconsistent b enef it s of gene t herapy using a single grow t h factor m ight also b e att ributable to t he lack of ideal vectors and lim ited progressive disea se, t riggering t he collateral for mation and neova scularization m ight b e ver y b enef icial in restoring t he blood flow to t he ischem ic limbs [49, 50] . MC-shPHD2 would t herefore b e an interesting alter native t reatment st rategy for t herap eutic angiogenesis in t he fut ure.
In conclusion, t he present st udy provides encouraging initial evidence for a new p otential t herap eutic approach for t riggering t he collateral for mation and neova scularization in PAD. Using a nonviral m inicircle vector carr ying shPHD2, HIF-1-alpha is upregulated t h rough PHD2 k nockdown, resulting in an improved p ost-ischem ic neova scularization in a hindlimb ischem ia mouse model. 
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SUPPLEMENTAL METHODS
A ngiography. Post mortem angiography of b ot h hindlimbs wa s p er for med using Microf il cont ra st agent (Flow tech, Carver, MA, USA) according to t he manufact urer's protocol. After t horacotomy, cont ra st fluid wa s injected into t he left vent ricle of t he mouse heart. Five m inutes b efore cont ra st injection, m ice were int ravenously injected wit h papaverine (50 mg/ml) for va sodilatation. The skin of b ot h hindlimbs wa s removed and X-rays were made. R NA ex t raction. To conf ir m t hat MC-shPHD2 could decrea se PHD2 mR NA levels and could increa se HIF-1-alpha protein levels in vivo a s compared to PL-shPHD2 or PBS, additional C57BL6 m ice were subjected to hindlimb ischem ia followed by injection of MC-shPHD2, PL-shPHD2, or PBS. Ga st rocnem ius muscles (n=27) were harvested 7 days after surger y for furt her analysis. Total R NA wa s ex t racted wit h Trizol reagent according to t he manufact urer's inst r uctions (Invit rogen). R NA wa s reverse-t ranscrib ed into cDNA using t he High Capacity R NA to cDNA kit (Applied Biosystems, Foster City, CA, USA) to a ssess t he mR NA expression levels of PHD2.
will b ecome redundant and will disapp ear, a process called pr uning, wherea s ot her collaterals will fully mat ure [42, 43] . For fut ure larger animal st udies t hat require a longer t herap eutic window, rep eated t ransfection using m inicircle vectors is fea sible wit h robust t ransgene activities, wit h lower host cellular and humoral im mune resp onses a s seen wit h rep eated injections of viral vectors [6] .
In t his st udy, we selected PHD2 a s t he target gene by downregulation of t he mouse PHD2 gene by MC-mediated shR NA inter ference, which leads to activation of downst ream angiogenic genes and proteins. In line wit h our result s, a recent rep ort showed t hat downregulation of PHD2 by shR NA enhanced neoangiogenesis in a mouse model of myocardial infarction [18] . In t his st udy, Bordoli et al. showed t hat PHD2 functions a s a t umor suppressor in xenografted t umors derived from brea st carcinoma. In t his resp ect, a s PHD inhibitors have b een develop ed for t he t reatment of PAD, t here are concer ns over p ossible side effect s of t hese inhibitors in t umor progression.
More encouragingly, ot hers have shown t hat genetic inactivation of PHD2 increa sed t he deliver y of chemot herap eutics to t he t umor and t hereby t heir anti-t umor and anti-meta static effect [46] . This st udy also showed t hat PHD2 haplodef iciency prevented ox idative damage, organ failure, and tissue loss. In addition, a random ized, double-blind, placeb o-cont rolled st udy using adenoviral HIF-1-alpha showed no evidence of promotion of t umor grow t h [47] . 
